ORIGINAL RESEARCH article

Front. Genet., 31 July 2020

Sec. Genetics of Common and Rare Diseases

Volume 11 - 2020 | https://doi.org/10.3389/fgene.2020.00813

Transcriptomic Changes Resulting From STK32B Overexpression Identify Pathways Potentially Relevant to Essential Tremor

  • 1. Department of Human Genetics, McGill University, Montreal, QC, Canada

  • 2. Montreal Neurological Institute, McGill University, Montreal, QC, Canada

  • 3. Department of Biomedical Sciences, Université de Montréal, Montreal, QC, Canada

  • 4. Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada

Abstract

Objective: Essential tremor (ET) is a common movement disorder that has a high heritability. A number of genetic studies have associated different genes and loci with ET, but few have investigated the biology of any of these genes. STK32B was significantly associated with ET in a large genome-wide association study (GWAS) and was found to be overexpressed in ET cerebellar tissue. The objective of this study is to determine the effects of overexpressed STK32B in cerebellar DAOY cells.

Methods: Here, we overexpressed STK32B RNA in human cerebellar DAOY cells and used an RNA-Seq approach to identify differentially expressed genes (DEGs) by comparing the transcriptome profile of these cells to one of the control DAOY cells.

Results: Pathway and gene ontology enrichment identified axon guidance, olfactory signaling, and calcium-voltage channels as significant. Additionally, we show that overexpressing STK32B affects transcript levels of previously implicated ET genes such as FUS.

Conclusion: Our results investigate the effects of overexpressed STK32B and suggest that it may be involved in relevant ET pathways and genes.

Introduction

Essential tremor (ET) is one of the most common movement disorders and is typically characterized by a kinetic tremor in the hand or arms (Elble, 2013). The severity tends to increase with age and may involve different regions such as the head, voice, or jaw (Haubenberger and Hallett, 2018). Previous studies investigating the histology of post-mortem tissue have pinpointed the cerebellum as a region of interest for ET (Gironell, 2014). Specifically, abnormalities with Purkinje cell axons and dendrites were found in ET brains (Axelrad et al., 2008). Furthermore, the olivocerebellar circuitry has been implicated in ET pathology and many calcium voltage channels are highly expressed in this circuitry (Schmouth et al., 2014).

The genetic etiology of ET has remained largely elusive and most studies have focused on common or rare variants and on looking for genetic overlap with other disorders (Houle et al., 2017; Liao et al., 2018). Twin studies have shown that ET has a concordance of 69–93% in monozygotic twins and 27–29% in dizygotic twins, which suggests that both genetic and environmental factors drive the onset and development of this complex trait (Tanner et al., 2001). A recent genome-wide association study (GWAS) identified a significant locus in STK32B and found that ET patients overexpressed STK32B in cerebellar tissue by comparison to healthy controls, suggesting potential implications of STK32B in ET (Müller et al., 2016). STK32B is transcribed and translated into YANK2, a serine/threonine kinase, that has not been well characterized. There have been several exome-wide studies that implicated different genetic variants as causes of ET. The first ET-implicated gene found through exome sequencing was the Fused in Sarcoma gene (FUS) (Merner et al., 2012). However, it is unclear whether these “ET” genes interact or have indirect effects on the expression of each other.

To understand the effects of overexpressed STK32B mRNA and identify pathways potentially relevant to ET, we overexpressed this gene in human cerebellar DAOY cells and compared transcriptomic changes in overexpressed cells and empty-vector controls using RNA sequencing. Several interesting pathways such as axon guidance, calcium ion transmembrane transport, and olfactory transduction were significantly enriched after overexpression of STK32B. We also identified previously implicated ET genes whose expression is dysregulated through the overexpression of STK32B, suggesting that overexpressed STK32B may have relevant downstream effects.

Results

Confirming Overexpression of STK32B

The STK32B stable cell lines had higher RNA expression of STK32B, which was detected by reverse-transcriptase qPCR (Supplementary Figure S1). RNA sequencing (RNA-Seq) also confirmed that the stable cell lines have higher STK32B RNA levels compared to controls (Figures 1, 2). The STK32B gene was the top significant differentially expressed gene (P = 7.07E-245, β = 3.1789).

FIGURE 1

FIGURE 2

Quality Control of RNA-Seq Analyses

The QQ-plot for differentially expressed genes (DEGs) did not show stratification or potential biases (Supplementary Figure S2). The M-A plot showed slight enrichment of downregulated genes compared to upregulated genes (Supplementary Figure S3). A principal component (PC) plot showed separation of controls and STK32B cell lines (Figure 3). Additionally, the dendrogram with heatmap shows that controls and STK32B cell lines are distinct (Supplementary Figure S4). The mean-variance plot shows the shrinkage under the sleuth model (Supplementary Figure S5).

FIGURE 3

STK32B Overexpression Affects the Expression of Previously Identified ET-Associated Genes

A total of 3,794 genes were found to be differentially expressed with a q-value < 0.05. There were 425 genes with a β > | 0.5| and q-value < 0.05. Amongst the 425 genes, there were several potentially relevant ET genes were dysregulated such as FUS (q-value = 0.007, β = 0.812) and two calcium voltage channel genes that are enriched in the olivocerebellar circuitry, CACNA1C (q-value = 0.011, β = 0.503) and CACNA1A (q-value = 0.030, β = 0.702) (Table 1). Several pathways and gene ontology terms were enriched for DEGs due to the overexpression of STK32B, including olfactory transduction (P = 2.68E-39), axon guidance (P = 9.50E-36), and calcium ion transmembrane transport (P = 3.02E-31) (Table 2).

TABLE 1

GenesP-valueQ-valueBeta
MTHFR3.22E-152.15E-12–1.0905696
SHF6.74E-072.72E-05–0.9995849
MAPT2.15E-066.81E-05–1.3021309
PPARGC1A6.87E-060.00016336–1.691415
SNCA0.000712360.0054543–0.4253643
FUS0.000908770.006537150.81221158
CACNA1C0.0016911430.0103666050.503658389
PPP2R2B0.001688560.01035793–0.7621076
GSTP10.002492190.01388975–0.2723091
GBA0.003269720.01712692–0.4716877
CACNA1A0.003069720.037133070.70202999
LINGO10.022060610.07248666–1.2292913
HNMT0.055460410.14360684–0.3656343
LRRK10.078431810.185200130.30296973
VDR0.079634030.187386510.26752548
MAPT0.082026360.19175911–1.786066
HMOX10.082588220.192787230.28335731
ALAD0.095081510.21263593–0.2562971
LRRK20.206289940.36752893–0.3644185
MAPT0.23955890.40824182–1.0324492
NOS10.260060330.43219823–1.558382
HMOX20.306618180.48353042–0.2005729
IL1B0.650884560.781831360.19430951
SLC1A20.666449450.79215448–0.2943051

Effects of STK32B perturbation on ET-implicated genes.

TABLE 2

Gene set IDGene set namePDatabase
KEGG_OLFACTORY_ TRANSDUCTIONOlfactory transduction2.68E-39KEGG
KEGG_PATHWAYS_ IN_CANCERPathways in cancer2.96E-28
KEGG_FOCAL_ ADHESIONFocal adhesion1.19E-26
KEGG_BLADDER_ CANCERBladder cancer6.53E-25
KEGG_ECM_ RECEPTOR_ INTERACTIONECM-receptor interaction8.38E-25
GO:0001650Fibrillar center1.13E-29GO Cellular
GO:0031012Extracellular matrix8.57E-27
GO:0001725Stress fiber1.24E-26
GO:0005925Focal adhesion2.82E-23
GO:0015629Actin cytoskeleton4.02E-22
REACTOME:R-HSA-381753Olfactory signaling pathway3.22E-46Reactome
REACTOME:R-HSA-418555G alpha (s) signaling events1.19E-29
REACTOME:R-HSA-3000170Syndecan interactions1.53E-27
REACTOME:R-HSA-2022090Assembly of collagen fibrils and other multimeric structures4.31E-25
REACTOME:R-HSA-1474290Collagen formation2.35E-24
GO:0050911Detection of chemical stimulus involved in sensory perception of smell1.00E-44GO Processes
GO:0007411Axon guidance9.50E-36
GO:0048146Positive regulation of fibroblast proliferation1.31E-33
GO:0070588Calcium ion transmembrane transport3.02E-31
GO:0050907Detection of chemical stimulus involved in sensory perception3.14E-31

Gene ontology and pathway analyses of differentially expressed genes.

Gene Network Analyses

To identify which cluster of DEGs drove the significant pathways, gene network analysis based on co-expression was done using and identified 14 different clusters within the DEGs (Supplementary Table S1). Analysis of the top 3 largest clusters for pathway enrichments found several similar pathways in different databases including axon guidance (P < 1.09E-12) in cluster 1 and calcium signaling pathway in cluster 3 (2.06E-05).

Discussion

The genetic etiology of ET is complex and likely explained by a combination of copy number variants, rare variants, gene-gene interactions and common variant drivers. One of the most significantly enriched pathways we identified was olfactory signaling and transduction. Previous reports have shown conflicting evidence about olfactory loss in ET (Applegate and Louis, 2005; Shah et al., 2008). It may be that ET patients with dysregulated olfactory signaling have overexpressed STK32B, which may contribute to the subset of ET patients with olfactory loss.

Interestingly, FUS was amongst the genes dysregulated when STK32B was overexpressed. In the exome familial ET study that identified FUS, we also found reduced mRNA levels for FUS (Merner et al., 2012). Similarly, the expression of FUS is lower when STK32B is overexpressed, suggesting an indirect relationship between the two genes. Additionally, two calcium voltage-gated channel genes, CACNA1C and CACNA1A were overexpressed. Enrichment analyses found the GO term calcium ion transmembrane transport to be highly significant in GO Biological Processes, suggesting that STK32B may play a role upstream of these genes. In the olivocerebellar circuitry, a system implicated in ET, is enriched for both of these genes (Mori et al., 1991; Schmouth et al., 2014). CACNA1A has been shown to be predominantly expressed in Purkinje cells, a cell type relevant to ET (Mori et al., 1991). Another enriched pathway was axon guidance. A previous study identified the TENM4 missense variant segregating within ET families (Hor et al., 2015). TENM4 is a regulator of axon guidance and myelination and Tenm4 knockout mice showed an ET phenotype, suggesting that axon guidance is important in ET (Hor et al., 2015). Similarly, overexpressed STK32B could be dysregulating important pathways relevant to axon guidance.

By sub-stratifying the overexpressed genes into different clusters that are co-expressed, several interesting pathways involving the cardiovascular system were identified. GO terms and pathways such as right ventricular cardiomyopathy in KEGG and angiogenesis in GO Biological Processes were found among the significant pathways in Table 3. In certain ET patients, beta-blockers can reduce tremor magnitude and frequency. Beta-blockers lower blood pressure and are used to treat irregular heart rhythm and other cardiovascular phenotypes. A common treatment for ET is propranolol, a beta-blocker. This was a drug developed for cardiovascular health that affects adrenergic activity, but still reduces tremor in ET individuals. This could suggest that overexpressed STK32B affects cardiovascular health, which may in turn affect or lead to the ET phenotype or that STK32B may be pleiotropic and affect the nervous and cardiovascular system differently.

TABLE 3

Gene set nameP-valueDatabaseCluster
Regulation of actin cytoskeleton1.03E-13KEGG1
Pathways in cancer1.23E-13
Axon guidance1.09E-12
Focal adhesion4.96E-12
Arrhythmogenic right ventricular cardiomyopathy (ARVC)4.63E-09
Fibrillar center1.13E-29GO Cellular
Extracellular matrix8.57E-27
Stress fiber1.24E-26
Focal adhesion2.82E-23
Actin cytoskeleton4.02E-22
Actin binding3.66E-15GO Function
Laminin binding2.37E-13
Insulin-like growth factor binding9.72E-13
Collagen binding3.73E-12
Protein heterodimerization activity5.54E-12
Cell migration involved in sprouting angiogenesis7.07E-18GO Processes
Cell migration2.94E-16
inactivation of MAPK activity3.31E-15
Cytoskeleton organization6.34E-15
Negative regulation of cell migration9.12E-15
Cell-extracellular matrix interactions7.16E-15Reactome
Signal transduction1.98E-13
Non-integrin membrane-ECM interactions2.58E-12
Signaling by Rho GTPases1.84E-11
EPHA-mediated growth cone collapse2.30E-11
RNA polymerase4.57E-13KEGG2
Pyrimidine metabolism1.37E-12
Alzheimer’s disease3.55E-11
Purine metabolism4.11E-11
GnRH signaling pathway1.84E-09
Nucleolus5.96E-19GO Cellular
Preribosome, large subunit precursor2.21E-18
Small-subunit processome5.13E-18
DNA-directed RNA polymerase III complex5.10E-15
DNA-directed RNA polymerase I complex1.85E-14
Pseudouridine synthase activity7.75E-16GO Function
RNA binding1.25E-15
snoRNA binding4.90E-14
rRNA binding3.55E-13
ATP-dependent RNA helicase activity5.23E-13
RNA secondary structure unwinding1.57E-16GO Processes
tRNA modification7.73E-16
Positive regulation of gene expression, epigenetic3.09E-15
Ribosomal large subunit biogenesis3.17E-15
Maturation of SSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA)3.32E-15
rRNA modification in the nucleus and cytosol3.38E-18Reactome
tRNA processing1.65E-17
tRNA modification in the nucleus and cytosol1.66E-16
rRNA processing9.91E-15
tRNA processing in the nucleus1.69E-14
RIG-I-like receptor signaling pathway1.24E-10KEGG3
Cytosolic DNA-sensing pathway1.92E-07
O-glycan biosynthesis1.163E-06
Focal adhesion1.36893E-06
Calcium signaling pathway2.06986E-05
Caveola2.00E-08GO Cellular
Proteinaceous extracellular matrix7.41E-08
Postsynaptic membrane2.45E-06
Microfibril4.99E-06
Extracellular matrix1.12E-05
Type I interferon receptor binding3.64E-07GO Function
Neuropeptide binding5.89E-07
Scavenger receptor activity6.23E-07
Calcium-dependent phospholipid binding9.44E-07
RNA binding2.46E-06
Response to mechanical stimulus8.42E-09GO Processes
Lung development1.55E-08
Negative regulation of neuron apoptotic process5.29E-08
Cellular response to hypoxia7.29E-08
Regulation of type I interferon-mediated signaling pathway1.11E-07
O-glycosylation of TSR domain-containing proteins3.73E-10Reactome
Defective B3GALTL causes Peters plus syndrome (PpS)5.15E-10
DDX58/IFIH1-mediated induction of interferon-alpha/beta1.29E-09
O-linked glycosylation4.91E-08
Diseases associated with O-glycosylation of proteins1.04E-07

Gene ontology and pathway analyses of differentially expressed gene for the three largest clusters based on co-expression.

Due to the heterogeneity of ET, it is likely that not all ET-affected individuals have overexpression of STK32B. One limitation of this study is that DAOY cells are a cancerous cell line and may not be the ideal model for understanding the transcriptome of Purkinje cells. Future studies on the effects of STK32B overexpression could use induced pluripotent stem cells differentiated into cells with Purkinje cells properties; such cells would likely have less biological noise. However, our findings support the idea that STK32B is a gene of interest for a subset of ET cases, and further investigations into how STK32B may interact with other genes are warranted.

Materials and Methods

Cell Culture and Plasmid Construction

The DAOY cell line was cultured in Eagle’s Minimum Essential Medium (EMEM) with 10% fetal bovine serum (FBS) at 37°C and 5% CO2 with the Glico Pen-Strep-Glutamine cocktail at 1×. Cells were passaged every 2 days at 80–90% confluence and at the same time. The cDNA of STK32B (NM_001306082.1) was inserted into a pcDNA3.1(+) vector containing a neomycin resistance gene, used as a selectable marker. This transcript was picked because it had the highest expression in the cerebellum based on GTEx 53 v7. The plasmid was transformed and expanded in XL10-Gold Escherichia coli strain (Stratagene). The cDNA of the plasmid was sent for Sanger sequencing to validate the gene sequence.

Transfection and Deriving Stable Cell Lines

The cells were transfected for 48 h with 8 ug of the vector of using the jetPRIME transfection reagent (Polyplus). A green fluorescent protein (GFP) control vector was used to assess and estimate transfection efficiency and optimize transfection parameters. Stable cell lines were established by subjecting transfected cells to G418 antibiotic at 1 μg/mL for 10 days and maintained at a concentration of 400 μg/mL for an additional 2 weeks. A kill curve was done to determine the ideal antibiotic selection. In parallel, empty pcDNA3.1(+) vector control lines were also grown and underwent antibiotic selection.

RNA Extraction and Sequencing

Total RNA was extracted using the RNeasy Mini Kit (Qiagen). The total RNA concentration was measured using the Synergy H4 microplate reader. RNA for the top three overexpressed STK32B cell lines and three empty-vector controls was sent to Macrogen Inc., for sequencing. RT-qPCR was used to confirm overexpression in the cell lines compared to controls. Preparation of the cDNA library was done with the TruSeq Stranded Total RNA Kit (Ilumina) with Ribo-Zero depletion. Sequencing was done on the NovaSeq 6000 at 150 bp paired-end reads with a total of 200M reads. Samples were randomized for cell lysis, RNA extraction, Ribo-Zero depletion, library preparation and sequencing to account for potential batch effects.

Data Processing and Quality Control

The FASTQ files were pseudo-aligned with Salmon using the Ensembl v94 annotation of the human genome (Patro et al., 2017). The data is available on the public repository of NCBI, Gene Expression Omnibus (GEO), with the GEO accession as GSE150393. It can be accessed with the following URL: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE150393. The parameters of Salmon included the following: 200 bootstraps with mapping validation, GC bias correction, sequencing bias correction, 4 range factorization bins, a minimum score fraction of 0.95 and VB optimization with a VB prior of 1e-5. The estimated counts were analyzed using sleuth to identify DEGs (Pimentel et al., 2017). A Wald test was used to get β values [log2(x + 0.5)]. Additionally, transcript-level aggregation was done against the Ensembl v94 annotation to determine gene-level differential expression. P-values were corrected using the Benjamini–Hochberg procedure to account for false discovery rate (FDR). The FDR threshold was set at 0.05. A PC plot and heatmap was done to identify clusters.

Pathway and Gene Set Enrichment Analysis

Pathway and gene set enrichment for relevant databases was done using Gene Network 2.0 (Deelen et al., 2019). To investigate genes with larger fold changes, only DEGs with a β > |0.5| were analyzed for pathway enrichments. Network clustering was done by grouping genes based on co-expression using Gene Network 2.0. Pathway analyses were also conducted with Gene Network 2.0 for the clusters using a Wilcoxon test. We included the top five significant pathways across different databases.

Statements

Data availability statement

The data is available on the public repository of NCBI, Gene Expression Omnibus (GEO), with the GEO accession as GSE150393. It can be accessed with the following URL: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE150393.

Ethics statement

The review board at the McGill University Health Center Research Ethics Board (MUHC REB) approved the study protocols (reference number IRB00010120).

Author contributions

CL conducted the experiments and analyses and drafted the manuscript. FS, VV, DR, FA, SD, GH, QH, and HC helped with experiments. AL and DS helped with bioinformatic analyses. PD and GR oversaw the study and drafting of the manuscript. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by a Canadian Institutes of Health Research Foundation Scheme grant (#332971). GR holds a Canada Research Chair in Genetics of the Nervous System and the Wilder Penfield Chair in Neurosciences. CL is a recipient of the Frederick Banting and Charles Best Canada Graduate Scholarship from the Canadian Institutes of Health Research (CIHR). FA is funded by the Fonds de Recherche du Québec-Santé (FRQS). GH is funded by the Canadian Institutes of Health Research (CIHR; FRN 159279).

Acknowledgments

The manuscript has been released as a pre-print at https://www.biorxiv.org/content/10.1101/552901v2.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2020.00813/full#supplementary-material

References

  • 1

    ApplegateL. M.LouisE. D. (2005). Essential tremor: mild olfactory dysfunction in a cerebellar disorder.Parkinsonism Relat. Disord.11399402. 10.1016/j.parkreldis.2005.03.003

  • 2

    AxelradJ. E.LouisE. D.HonigL. S.FloresI.RossG. W.PahwaR.et al (2008). Reduced Purkinje cell number in essential tremor: a postmortem study.Arch. Neurol.65101107.

  • 3

    DeelenP.van DamS.HerkertJ. C.KarjalainenJ. M.BruggeH.AbbottK. M.et al (2019). Improving the diagnostic yield of exome- sequencing by predicting gene–phenotype associations using large-scale gene expression analysis.Nat. Commun.10:2837.

  • 4

    ElbleR. J. (2013). What is essential tremor?Curr. Neurol. Neurosci. Rep.13:353.

  • 5

    GironellA. (2014). The GABA hypothesis in essential tremor: lights and shadows.Tremor. Hyperkinet. Mov.4:254. 10.5334/tohm.229

  • 6

    HaubenbergerD.HallettM. (2018). Essential TREMOR.N. Engl. J. Med.37818021810.

  • 7

    HorH.FrancescattoL.BartesaghiL.Ortega-CuberoS.KousiM.Lorenzo-BetancorO.et al (2015). Missense mutations in TENM4, a regulator of axon guidance and central myelination, cause essential tremor.Hum. Mol. Genet.2456775686. 10.1093/hmg/ddv281

  • 8

    HouleG.SchmouthJ.-F.LeblondC. S.AmbalavananA.SpiegelmanD.LaurentS. B.et al (2017). Teneurin transmembrane protein 4 is not a cause for essential tremor in a Canadian population.Mov. Disord.32292295. 10.1002/mds.26753

  • 9

    LiaoC.HouleG.HeQ.LaporteA. D.GirardS. L.DionP. A.et al (2018). Investigating the association and causal relationship between restless legs syndrome and essential tremor.Parkinsonism Relat. Disord.61238240. 10.1016/j.parkreldis.2018.10.022

  • 10

    MernerN. D.GirardS. L.CatoireH.BourassaC. V.BelzilV. V.RivièreJ. B.et al (2012). Exome sequencing identifies FUS mutations as a cause of essential tremor.Am. J. Hum. Genet.91313319. 10.1016/j.ajhg.2012.07.002

  • 11

    MoriY.FriedrichT.KimM.-S.MikamiA.NakaiJ.RuthP.et al (1991). Primary structure and functional expression from complementary DNA of a brain calcium channel.Nature350398402. 10.1038/350398a0

  • 12

    MüllerS. H.GirardS. L.HopfnerF.MernerN. D.BourassaC. V.LorenzD.et al (2016). Genome-wide association study in essential tremor identifies three new loci.Brain13931633169.

  • 13

    PatroR.DuggalG.LoveM. I.IrizarryR. A.KingsfordC. (2017). Salmon provides fast and bias-aware quantification of transcript expression.Nat. Methods14417419. 10.1038/nmeth.4197

  • 14

    PimentelH.BrayN. L.PuenteS.MelstedP.PachterL. (2017). Differential analysis of RNA-seq incorporating quantification uncertainty.Nat. Methods14687690. 10.1038/nmeth.4324

  • 15

    SchmouthJ.-F.DionP. A.RouleauG. A. (2014). Genetics of essential tremor: From phenotype to genes, insights from both human and mouse studies.Prog. Neurobiol.11119. 10.1016/j.pneurobio.2014.05.001

  • 16

    ShahM.MuhammedN.FindleyL. J.HawkesC. H. (2008). Olfactory tests in the diagnosis of essential tremor.Parkinsonism Relat. Disord.14563568. 10.1016/j.parkreldis.2007.12.006

  • 17

    TannerC. M.GoldmanS. M.LyonsK. E.AstonD. A.TetrudJ. W.WelshM. D.et al (2001). Essential tremor in twins: an assessment of genetic vs environmental determinants of etiology.Neurology5713891391. 10.1212/wnl.57.8.1389

Summary

Keywords

STK32B, essential tremor, transcriptome, FUS, neurology

Citation

Liao C, Sarayloo F, Vuokila V, Rochefort D, Akçimen F, Diamond S, Houle G, Laporte AD, Spiegelman D, He Q, Catoire H, Dion PA and Rouleau GA (2020) Transcriptomic Changes Resulting From STK32B Overexpression Identify Pathways Potentially Relevant to Essential Tremor. Front. Genet. 11:813. doi: 10.3389/fgene.2020.00813

Received

03 March 2020

Accepted

06 July 2020

Published

31 July 2020

Volume

11 - 2020

Edited by

Andrew Landstrom, Duke University, United States

Reviewed by

Fan Jin, Zhejiang University, China; Yejun Wang, Shenzhen University, China; Angela Cánovas, University of Guelph, Canada

Updates

Copyright

*Correspondence: Guy A. Rouleau,

This article was submitted to Genetics of Common and Rare Diseases, a section of the journal Frontiers in Genetics

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics